Optic neuritis: a narrative review on biomarkers and imaging in differential diagnosis
DOI:
https://doi.org/10.33448/rsd-v14i11.49910Keywords:
Optic neuritis, Neurology, Differential diagnosis, Optical Coherence tomography, Ophthalmology.Abstract
Optic neuritis (ON), an acute inflammation of the optic nerve, is the most common optic neuropathy in young adults and constitutes a neuro-ophthalmologic emergency. For years, ON was viewed primarily as a sentinel event for Multiple Sclerosis (MS). However, recent discoveries, particularly serum antibodies against aquaporin-4 (AQP4-IgG) and myelin oligodendrocyte glycoprotein (MOG-IgG), have redefined the diagnostic landscape. This narrative review aims to synthesize the most recent scientific evidence (2020-2024) on the ON approach, focusing on the clinical, serological, and imaging findings that differentiate these etiologies. Methods: A narrative review was conducted, searching PubMed, SciELO, and LILACS for publications from 2020 to 2024 using relevant descriptors. Results: The synthesized literature indicates that atypical presentations (such as bilaterality, severe vision loss, pronounced papillitis, poor recovery) mandate immediate serological investigation. MOGAD-ON often presents with significant disc edema but a strong steroid response, whereas NMOSD-ON (AQP4+) is linked to a poor visual prognosis and high relapse risk. Tools like Optical Coherence Tomography (OCT) are essential for quantifying axonal damage (retinal nerve fiber layer), which is demonstrably more severe in NMOSD. Therapeutic management differs drastically; MS therapies can be ineffective or harmful in NMOSD. Conclusion: The approach to optic neuritis is no longer monolithic. The ophthalmologist plays a central role in the initial suspicion and must use biomarkers and imaging (OCT, MRI) for precise etiological classification, which dictates acute therapy and the need for chronic immunosuppression.
References
Bennett, J. L., et al. (2023). Diagnosis and classification of MOGAD. The Lancet Neurology, 22(4), 348-362.
Bichuetti, D. B., et al. (2021). Neuromyelitis optica spectrum disorders: a review with a focus on children and adolescents. Arquivos de Neuro-Psiquiatria, 79(6), 535-546.
Chen, J. J., Pittock, S. J., & Flanagan, E. P. (2020). Optic neuritis in the era of aquaporin-4 and MOG antibodies. Journal of Neuro-Ophthalmology, 40(1), 89-97.
Chen, X., et al. (2023). Retinal structural and microvascular changes in myelin oligodendrocyte glycoprotein antibody disease and neuromyelitis optica spectrum disorder: An OCT/OCTA study. Frontiers in Immunology, 14, 1029124.
Dubuy, A., et al. (2023). Beyond myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: Alternative causes of optic neuritis. International Journal of Molecular Sciences, 24(21), 15986.
Garcia-Gutierrez, G., et al. (2023). Clinical outcomes and prognostic factors in patients with optic neuritis related to NMOSD and MOGAD in distinct ethnic groups from Latin America. Multiple Sclerosis and Related Disorders, 73, 104648.
Kale, N. (2023). The neuro-ophthalmological manifestations of NMOSD and MOGAD—a comprehensive review. Eye, 37(11), 2237-2248.
Kim, H. J., et al. (2023). Diagnosis and treatment of neuromyelitis optica spectrum disorder (NMOSD). Experimental & Molecular Medicine, 55, 1167-1178.
Mendanha, D. B. A., et al. (2024). Neuropatia óptica isquêmica e envelhecimento: revisão sistemática e metanálise. Revista Brasileira de Oftalmologia, 83, e0054.
Nasr, J., et al. (2024). Optical coherence tomography angiography measurements in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody disease: A systematic review and meta-analysis. European Journal of Ophthalmology, 34(5), 2003-2016.
Optic Neuritis Study Group. (1997). The 5-year risk of MS after optic neuritis. Experience of the Optic Neuritis treatment trial. Neurology, 49(6), 1404-1413.
Paplińska, M., et al. (2024). Visual outcome measures in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Frontiers in Neurology, 14, 1314986.
Pereira, A. S. et al. (2018). Metodologia da pesquisa científica. [free ebook]. Santa Maria: Editora da UFSM.
Pisani, L., et al. (2023). Updates in NMOSD and MOGAD diagnosis and treatment: A tale of two CNS autoimmune inflammatory disorders. Cells, 12(22), 2650.
Rother, E. T. (2007). Revisão sistemática x revisão integrativa. Acta Paulista de Enfermagem. 20(2), 5-6.
Sá, M. J. (2021). Neurite óptica: um desafio diagnóstico e terapêutico. Arquivos de Neuro-Psiquiatria, 79(9), 848-857.
Silva, D. B., et al. (2023). Neuromielite Óptica: Abordagens Diagnósticas. In R. M. C. Pereira (Org.), Tópicos em Ciências da Saúde 28 (cap. 14, pp. 187-194). Atena Editora.
Spillers, N. J., et al. (2024). A comparative review of typical and atypical optic neuritis: Advancements in treatments, diagnostics, and prognosis. Cureus, 16(3), e56178.
Stiebel-Kalish, H., et al. (2023). The ophthalmologist's role in diagnosing MOGAD and NMOSD. Eye, 37, 2249-2259.
Vieira, G. R., Diniz, D. S., & Monteiro, M. L. R. (2020). Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis: an update. Arquivos Brasileiros de Oftalmologia, 83(2), 160-168.
Zakrzewska-Pniewska, B., et al. (2024). Update on diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) — recommendations of Section of Multiple Sclerosis and Neuroimmunology of Polish Neurological Society. Neurologia i Neurochirurgia Polska, 58(1), 1-13.
Žorić, L., & Čolak, E. (2024). Review of atypical optic neuritis. Neurological Sciences, 45(1), 81-91.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 João Pedro Gambetta Polay, Renata Nadal Bayer, João Matheus Schirlo, Juliane Tramontim, Nathan Nabozny
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
